Bimagrumab (BYM338) is a human monoclonal antibody developed by Novartis to treat pathological muscle loss and weakness. On August 20, 2013 it was announced that bimagrumab was granted breakthrough therapy designation for sporadic inclusion body myositis (sIBM) by US Food and Drug Administration.
Bimagrumab is currently entering Phase II development, with some research indicating clinical effects. http://www.ncbi.nlm.nih.gov/pubmed/25381300
|This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.|